Research Study

A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Principal Investigator 
Patrick Ma

Overview

Body Locations and Systems 
Uveitis
ClinicalTrials.gov# 
NCT01148225
Status 
Closed to Recruitment
Study Start/End 
Oct 23, 2012 to Sep 15, 2018
Locations 
Vancouver General Hospital
Name/Title 
Theresa Wiens, Study Coordinator
Phone 
604-875-4111 ext.62544
Purpose of Study 

There is an unmet medical need in non-infectious intermediate-, posterior- and pan uveitis. These types of uveitis are at a higher risk for vision loss compared to anterior uveitis. Patients with these types of uveitis are often treated with chronic corticosteroids. The use of chronic corticosteroids is linked with predictable long-term side effects. The objective of this study is to evaluate the long term efficacy and safety of adalimumab subjects with non-infectious intermediate-, posterior- or pan-uveitis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.